Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 6Completed 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 2Stomach Neoplasms 1Sarcoma, Clear Cell 1Rectal Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms by Site 1Multiple Myeloma 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Digestive System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

Carboplatin 103Pemetrexed 96pembrolizumab 78Docetaxel 78Cisplatin 72Paclitaxel 70Erlotinib Hydrochloride 50Gemcitabine 48Radiotherapy 42Nivolumab 35Bevacizumab 35atezolizumab 24Radiosurgery 24durvalumab 20Cyclophosphamide 17130-nm albumin-bound paclitaxel 15Vinorelbine 14Taxes 14Radiation 14Etoposide 13Ipilimumab 12Albumin-Bound Paclitaxel 12avelumab 11Drug Therapy 10Cetuximab 10spartalizumab 9Sorafenib 9trametinib 8osimertinib 8capmatinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Non-Small-Cell Lung × dostarlimab × Clear all
NCT04581824 2025-08-08

Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

GlaxoSmithKline

Phase 2 Terminated
243 enrolled 21 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡